# A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

> **NCT05835011** · PHASE2 · TERMINATED · sponsor: **Astex Pharmaceuticals, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Decitabine/Cedazuridine
- **DRUG:** Magrolimab

## Key facts

- **NCT ID:** NCT05835011
- **Lead sponsor:** Astex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-27
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-08-21
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Termination due to discontinuation of magrolimab development in MDS.
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05835011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05835011, "A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05835011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*